Product Name :
Fenoterol hydrobromide
Description:
Fenoterol hydrobromide (Th-1165a), a sympathomimetic agent, is a selective and orally active β2-adrenoceptor agonist. Fenoterol hydrobromide is an effective bronchodilator and can be used for bronchospasm associated with asthma, bronchitis and other obstructive airway diseases research.
CAS:
1944-12-3
Molecular Weight:
384.26
Formula:
C17H22BrNO4
Chemical Name:
5-(1-hydroxy-2-[1-(4-hydroxyphenyl)propan-2-yl]aminoethyl)benzene-1,3-diol; bromohydrogen
Smiles :
Br.CC(CC1C=CC(O)=CC=1)NCC(O)C1C=C(O)C=C(O)C=1
InChiKey:
SGZRQMALQBXAIQ-UHFFFAOYSA-N
InChi :
InChI=1S/C17H21NO4.BrH/c1-11(6-12-2-4-14(19)5-3-12)18-10-17(22)13-7-15(20)9-16(21)8-13;/h2-5,7-9,11,17-22H,6,10H2,1H3;1H
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.Insulin (swine) custom synthesis
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.Clascoterone web
Additional information:
Fenoterol hydrobromide (Th-1165a), a sympathomimetic agent, is a selective and orally active β2-adrenoceptor agonist. Fenoterol hydrobromide is an effective bronchodilator and can be used for bronchospasm associated with asthma, bronchitis and other obstructive airway diseases research.|Product information|CAS Number: 1944-12-3|Molecular Weight: 384.26|Formula: C17H22BrNO4|Synonym:|Th-1165a|Phenoterol hydrobromide|Chemical Name: 5-(1-hydroxy-2-[1-(4-hydroxyphenyl)propan-2-yl]aminoethyl)benzene-1,3-diol; bromohydrogen|Smiles: Br.CC(CC1C=CC(O)=CC=1)NCC(O)C1C=C(O)C=C(O)C=1|InChiKey: SGZRQMALQBXAIQ-UHFFFAOYSA-N|InChi: InChI=1S/C17H21NO4.BrH/c1-11(6-12-2-4-14(19)5-3-12)18-10-17(22)13-7-15(20)9-16(21)8-13;/h2-5,7-9,11,17-22H,6,10H2,1H3;1H|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : ≥ 100 mg/mL (260.24 mM). H2O : 25 mg/mL (65.06 mM; Need ultrasonic).|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.PMID:33360998 |Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|Fenoterol (1 μM; pre-incubated 30 minutes) treatment reduces AICAR-induced AMPK activation, NF-κB activation and TNF-α release, and also significantly downregulates the elevated phosphorylation levels of AMPK. Fenoterol inhibits lipopolysaccharide (LPS)-induced AMPK activation and inflammatory cytokine production in THP-1 cells. Fenoterol is also a potent exosome biogenesis and/or secretion activator in PC cells.|In Vivo:|Fenoterol (0.7 mg/kg; intraperitoneal injection; twice a day; for 3 weeks) treatment suppresses mechanical allodynia during chronic treatment.|References:|R C Heel, et al. Fenoterol: a review of its pharmacological properties and therapeutic efficacy in asthma. Drugs. 1978 Jan;15(1):3-32.Wei Wang, et al. Anti-inflammatory activities of fenoterol through β-arrestin-2 and inhibition of AMPK and NF-κB activation in AICAR-induced THP-1 cells. Biomed Pharmacother. 2016 Dec;84:185-190.Nada Choucair-Jaafar, et al. Beta2-adrenoceptor agonists alleviate neuropathic allodynia in mice after chronic treatment. Br J Pharmacol. 2009 Dec;158(7):1683-94.Products are for research use only. Not for human use.|